Skip to main content
. Author manuscript; available in PMC: 2017 Oct 3.
Published in final edited form as: Oncogene. 2017 Apr 3;36(32):4653–4661. doi: 10.1038/onc.2017.95

Figure 3. Pre-cancerous Eμ-myc B cells exhibit relative resistance to Btk inhibition by ibrutinib.

Figure 3

CD19+, IgM+ splenic B cells from Eμ-myc or wild-type mice at rest (A) or 10 minutes after IgM ligation (B) were pretreated with escalating concentrations of ibrutinib, and Btk phosphorylation was measured by intracellular phospho-flow cytometry. Mean fluorescence intensities (MFI) of representative experiments containing 3 mice of each genotype are shown. Error bars represent SEM; *p=0.007, **p≤0.025, ***p≤0.04.